AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9762482 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle biopsy of the right vastus lateralis muscle
Number of subjects: 19
Study 9762482 — intervention group
Group type: COMPARATOR
Intervention: Isokinetic testing for knee extension and flexion
Number of subjects: 19
Study 7530601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled serum specimens (10 specimens pooled)
Number of subjects: 0
Study 3246316 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine posture during dynamic exercise
Number of subjects: 20
Study 3246316 — intervention group
Group type: COMPARATOR
Intervention: Upright posture during dynamic exercise
Number of subjects: 20
Study 29590407 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Number of subjects: 346
Study 29590407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346
Study 25070967 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed tailored interactive DVD
Number of subjects: 1681
Study 25070967 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored telephone counseling
Number of subjects: 1681
Study 25070967 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1681
Study 25581711 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus sheath block using bupivacaine plus adrenaline
Number of subjects: 0
Study 25581711 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 0
Study 23062837 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX), mean daily dosage 71.6±14.9mg, treatment duration 12 weeks
Number of subjects: 43
Study 23062837 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 43
Study 23062837 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 43
Study 23062837 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study 21741092 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass AIT (Phleum pratense grass pollen allergen extract), once-daily for 8 to 10 weeks
Number of subjects: 276
Study 21741092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 18077218 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 106
Study 17070287 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on the simulator (2 sessions of 30 minutes each)
Number of subjects: 63
Study 17070287 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further training)
Number of subjects: 63
Study 12569211 — intervention group
Group type: EXPERIMENTAL
Intervention: low‐flow‐high‐pressure IMT
Number of subjects: 24
Study 12569211 — intervention group
Group type: EXPERIMENTAL
Intervention: high‐flow‐low‐pressure IMT
Number of subjects: 24
Study 12569211 — intervention group
Group type: EXPERIMENTAL
Intervention: intermediate flow‐pressure IMT
Number of subjects: 24
Study 12569211 — intervention group
Group type: COMPARATOR
Intervention: no IMT
Number of subjects: 24
Study 12569211 — intervention group
Group type: COMPARATOR
Intervention: detraining group (no IMT)
Number of subjects: 24
Study 12569211 — intervention group
Group type: EXPERIMENTAL
Intervention: maintenance group (IMT 2 d.wk(‐1))
Number of subjects: 24
Study 11124669 — intervention group
Group type: COMPARATOR
Intervention: Anterior transposition of the inferior oblique muscle (ATIO) without resection
Number of subjects: 30
Study 11124669 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior transposition of the inferior oblique muscle (ATIO) with a 7-mm resection
Number of subjects: 30
Study 11124669 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (standard ATIO and ATIO with resection)
Number of subjects: 30
Study 8777215 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-minute exercise protocol
Number of subjects: 9
Study 8777215 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-minute exercise protocol
Number of subjects: 9
Study 8777215 — intervention group
Group type: COMPARATOR
Intervention: Both protocols
Number of subjects: 9
Study 1328364 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg) + Benazepril (10 mg)
Number of subjects: 9
Study 1328364 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (20 mg)
Number of subjects: 9
Study 1328364 — intervention group
Group type: COMPARATOR
Intervention: Benazepril (10 mg)
Number of subjects: 9
Study 6108817 — intervention group
Group type: EXPERIMENTAL
Intervention: SKF 92 657 at 1.0 mg/kg
Number of subjects: 0
Study 6108817 — intervention group
Group type: EXPERIMENTAL
Intervention: SKF 92 657 at 2.0 mg/kg
Number of subjects: 0
Study 6108817 — intervention group
Group type: EXPERIMENTAL
Intervention: SKF 92 657 at 4.0 mg/kg
Number of subjects: 0
Study 6108817 — intervention group
Group type: EXPERIMENTAL
Intervention: SKF 92 657 at 8.0 mg/kg
Number of subjects: 0
Study 6108817 — intervention group
Group type: EXPERIMENTAL
Intervention: SKF 92 657 continued for 7 days
Number of subjects: 0
Study 6108817 — intervention group
Group type: EXPERIMENTAL
Intervention: SKF 92 657 during dynamic exercise
Number of subjects: 0
Study 31159849 — intervention group
Group type: EXPERIMENTAL
Intervention: ASICA intervention (tablet-based digital intervention to prompt and support TSSE)
Number of subjects: 240
Study 31159849 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 240
Study 27853163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan 200 mg QD, uptitrated to 400 mg QD if BP uncontrolled after 4 weeks, followed by amlodipine 5-10 mg and hydrochlorothiazide 6.25-25 mg if needed
Number of subjects: 341
Study 27853163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan 200 mg QD
Number of subjects: 341
Study 25483230 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein and Zeaxanthin supplements (n=54)
Number of subjects: 69
Study 25483230 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=15)
Number of subjects: 69
Study 23729939 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced ENT surgeons
Number of subjects: 97
Study 23729939 — intervention group
Group type: COMPARATOR
Intervention: Nonexperienced ENT surgeons
Number of subjects: 97
Study 20390272 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard pushable coils
Number of subjects: 50
Study 20390272 — intervention group
Group type: EXPERIMENTAL
Intervention: Interlock detachable coils (IDC)
Number of subjects: 50
Study 19845256 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 10% phenylephrine cream
Number of subjects: 12
Study 19845256 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream (Control)
Number of subjects: 12
Study 17893000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pumping (IABP)
Number of subjects: 16
Study 17409898 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and gemcitabine (DG)
Number of subjects: 133
Study 17409898 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel and cisplatin (DC)
Number of subjects: 133
Study 14573714 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise programme (8 weeks, five shoulder stretching and strengthening exercises)
Number of subjects: 67
Study 14573714 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise programme
Number of subjects: 67
Study 14573714 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 67
Study 10084633 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg/day
Number of subjects: 195
Study 10084633 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 50 mg/day
Number of subjects: 195
Study 10084633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 8640150 — intervention group
Group type: EXPERIMENTAL
Intervention: Broncho-Vaxom
Number of subjects: 16
Study 8640150 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 healthy persons)
Number of subjects: 16
Study 2277573 — intervention group
Group type: EXPERIMENTAL
Intervention: Touhy needle pointed upward (parallel to the ligament flavum)
Number of subjects: 40
Study 2277573 — intervention group
Group type: COMPARATOR
Intervention: Touhy needle pointed caudally
Number of subjects: 40
Study 6786071 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-calorie replacement therapy (immediate sensitization to dinitrochlorobenzene)
Number of subjects: 50
Study 6786071 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-calorie replacement therapy (sensitization after 1 week)
Number of subjects: 50
Study 6786071 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-calorie replacement therapy (sensitization after 2 weeks)
Number of subjects: 50
Study 6786071 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-calorie replacement therapy (sensitization after 3 weeks)
Number of subjects: 50
Study 6786071 — intervention group
Group type: EXPERIMENTAL
Intervention: Attempted sensitization before refeeding in children with total serum proteins < 4.5 g/dl
Number of subjects: 50
Study 31390688 — intervention group
Group type: EXPERIMENTAL
Intervention: SFE with NMES
Number of subjects: 36
Study 31390688 — intervention group
Group type: COMPARATOR
Intervention: SFE alone
Number of subjects: 36
Study 28549665 — intervention group
Group type: EXPERIMENTAL
Intervention: High nitrate‐containing beetroot juice (BRJ) consumed daily (8 mmol nitrate for HTN) or three times a week (6.1 mmol nitrate for HFpEF)
Number of subjects: 46
Study 28549665 — intervention group
Group type: COMPARATOR
Intervention: Placebo (beet juice beverage with the nitrate removed)
Number of subjects: 46
Study 28549665 — intervention group
Group type: EXPERIMENTAL
Intervention: High nitrate‐containing beetroot juice (BRJ)
Number of subjects: 46
Study 28549665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 28549665 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BRJ and placebo
Number of subjects: 46
Study 25163639 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic preparation containing Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus plantarum, Bifidobacterium lactis, fructooligosaccharide, galactooligosaccharide, colostrums and lactoferrin (NBL probiotic ATP®)
Number of subjects: 210
Study 25163639 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 210
Study 23474363 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (830 mg/m² twice daily, Monday to Friday) with radiation (50.4 Gy in 28 fractions)
Number of subjects: 74
Study 23474363 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (300 mg/m² once per week) with radiation (50.4 Gy in 28 fractions)
Number of subjects: 74
Study 23474363 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 74
Study 23474363 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 74
Study 21320365 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g RBO spread (RBOS)
Number of subjects: 80
Study 21320365 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g phytosterol-enriched spread (PS)
Number of subjects: 80
Study 21320365 — intervention group
Group type: COMPARATOR
Intervention: 20 g standard spread (SS)
Number of subjects: 80
Study 21320365 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g RBOS plus 30 ml RBO
Number of subjects: 80
Study 21320365 — intervention group
Group type: COMPARATOR
Intervention: 20 g SS plus 30 ml sunflower oil
Number of subjects: 80
Study 18487628 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 1043
Study 18487628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1043
Study 16686387 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered hypertonic saline (HS)
Number of subjects: 60
Study 16686387 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline (NS)
Number of subjects: 60
Study 16686387 — intervention group
Group type: COMPARATOR
Intervention: No spray (control)
Number of subjects: 60
Study 14748452 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training (2 hours/week for 6 weeks)
Number of subjects: 37
Study 14748452 — intervention group
Group type: COMPARATOR
Intervention: Control group (47 young adolescents and a parent who did not participate in the training)
Number of subjects: 37
Study 10788675 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (1-h pedaling on a bicycle ergometer between 13.00 and 14.00 h)
Number of subjects: 63
Study 10788675 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light treatment (2-h exposure to 2500 lux between 14.00 and 16.00 h)
Number of subjects: 63
Study 10788675 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 63
Study 10788675 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light treatment
Number of subjects: 63
Study 10788675 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise and bright light treatment
Number of subjects: 63
Study 8840941 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous push of iron dextran 100 mg over 2 minutes (undiluted)
Number of subjects: 10
Study 8840941 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of iron dextran 100 mg over 30 minutes
Number of subjects: 10
Study 8840941 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-minimization analysis of intravenous push administration
Number of subjects: 10
Study 1531488 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic manipulation
Number of subjects: 63
Study 1531488 — intervention group
Group type: COMPARATOR
Intervention: Stroking massage
Number of subjects: 63
Study 1531488 — intervention group
Group type: COMPARATOR
Intervention: Corset
Number of subjects: 63
Study 1531488 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous muscular stimulation (TMS)
Number of subjects: 63
Study 6401911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteine‐HCl supplemented total parenteral nutrition
Number of subjects: 0
Study 6401911 — intervention group
Group type: COMPARATOR
Intervention: Automated amino acid analysis measuring 1/2 cystine
Number of subjects: 0
Study 31014060 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM splints and patient specific osteosynthesis for maxillary positioning
Number of subjects: 32
Study 31014060 — intervention group
Group type: COMPARATOR
Intervention: Occlusal wafers fabricated on a semi‐adjustable articulator
Number of subjects: 32
Study 30382737 — intervention group
Group type: EXPERIMENTAL
Intervention: iDOVE intervention (cognitive-behavioral therapy and motivational interviewing-based intervention with a brief in-ED session and 8 weeks of automated text-message daily mood queries)
Number of subjects: 116
Study 30382737 — intervention group
Group type: COMPARATOR
Intervention: Control (brief in-ED presentation and twice-weekly text messages on healthy behaviors)
Number of subjects: 116
Study 27022679 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 50,000 IU/wk Vitamin D3 (cholecalciferol) for 52 weeks
Number of subjects: 746
Study 27022679 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group) for 52 weeks
Number of subjects: 746
Study 27022679 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 50,000 IU/wk Vitamin D3 (cholecalciferol) for 52 weeks (stratified by depression types)
Number of subjects: 746
Study 24964217 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine infusion
Number of subjects: 40
Study 24964217 — intervention group
Group type: COMPARATOR
Intervention: Control (physiologic saline)
Number of subjects: 40
Study 22364367 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of the fascia during placement of the anastomotic sutures
Number of subjects: 260
Study 22364367 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral irrigation
Number of subjects: 260
Study 22364367 — intervention group
Group type: EXPERIMENTAL
Intervention: Both involvement of the fascia and urethral irrigation
Number of subjects: 260
Study 22364367 — intervention group
Group type: COMPARATOR
Intervention: Neither involvement of the fascia nor urethral irrigation
Number of subjects: 260
Study 22364367 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall trial methodology
Number of subjects: 260
Study 20630682 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (nadroparin 180 anti-activated factor X units once daily for 10 days) plus compression therapy for three months
Number of subjects: 107
Study 20630682 — intervention group
Group type: COMPARATOR
Intervention: Compression therapy alone
Number of subjects: 107
Study 17959578 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (400 IU)
Number of subjects: 0
Study 17959578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15222593 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention (counseling session and health information packet)
Number of subjects: 194
Study 15222593 — intervention group
Group type: COMPARATOR
Intervention: Control group (health information packet only)
Number of subjects: 194
Study 11237159 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouraged to self‐propel
Number of subjects: 40
Study 11237159 — intervention group
Group type: COMPARATOR
Intervention: Discouraged from self‐propulsion
Number of subjects: 40
Study 9203881 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (100 micrograms in 1 ml of saline)
Number of subjects: 36
Study 9203881 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (100 micrograms in 1 ml of saline)
Number of subjects: 36
Study 9203881 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (1 ml)
Number of subjects: 36
Study 7970115 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dialysis prescription using urea kinetic modelling (UKM)
Number of subjects: 56
Study 7970115 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 56
Study 3308737 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium treatment
Number of subjects: 60
Study 3308737 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid (1 g twice daily)
Number of subjects: 60
Study 3308737 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Calcium and Ascorbic acid)
Number of subjects: 60
Study 29028973 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn MVA85A vaccination (1 × 10^8 PFU)
Number of subjects: 248
Study 29028973 — intervention group
Group type: COMPARATOR
Intervention: Candin® control
Number of subjects: 248
Study 27225876 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 71
Study 27225876 — intervention group
Group type: EXPERIMENTAL
Intervention: 15° angle reverse Trendelenburg position
Number of subjects: 71
Study 27225876 — intervention group
Group type: EXPERIMENTAL
Intervention: 20° angle reverse Trendelenburg position
Number of subjects: 71
Study 25200399 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 989
Study 25200399 — intervention group
Group type: EXPERIMENTAL
Intervention: AREDS formulation (AF)
Number of subjects: 989
Study 25200399 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 989
Study 25200399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 989
Study 23408046 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hydrostatic pressure system (group P)
Number of subjects: 108
Study 23408046 — intervention group
Group type: COMPARATOR
Intervention: Saline-filled syringe (group C)
Number of subjects: 108
Study 23408046 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study 20048183 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (IDA3; 12 mg/m(2)/d x 3 days)
Number of subjects: 468
Study 20048183 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (IDA4; 12 mg/m(2)/d x 4 days)
Number of subjects: 468
Study 20048183 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin (DNR; 80 mg/m(2)/d x 3 days)
Number of subjects: 468
Study 20048183 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-2 (rIL-2; 5 x 10(6) U/m(2) x 5 days each month for 12 months)
Number of subjects: 468
Study 20048183 — intervention group
Group type: COMPARATOR
Intervention: Standard doses of idarubicin (IDA3; 12 mg/m(2)/d x 3 days)
Number of subjects: 468
Study 20048183 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy with rIL-2
Number of subjects: 468
Study 18221472 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri supplementation
Number of subjects: 109
Study 18221472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 16635225 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-11 (1 mg once weekly)
Number of subjects: 51
Study 16635225 — intervention group
Group type: COMPARATOR
Intervention: prednisolone (60 mg/day)
Number of subjects: 51
Study 12792544 — intervention group
Group type: EXPERIMENTAL
Intervention: AlloDerm (LifeCell) repair
Number of subjects: 25
Study 12792544 — intervention group
Group type: COMPARATOR
Intervention: GoreTex (W.L. Gore) repair
Number of subjects: 25
Study 12792544 — intervention group
Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 25
Study 10360200 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract restorations
Number of subjects: 0
Study 10360200 — intervention group
Group type: COMPARATOR
Intervention: Tytin restorations
Number of subjects: 0
Study 7492424 — intervention group
Group type: EXPERIMENTAL
Intervention: Health check with screening for cardiovascular risk factors, lung and liver function, fitness, sight and hearing, and optional HIV test; written feedback from general practitioner
Number of subjects: 1370
Study 7492424 — intervention group
Group type: EXPERIMENTAL
Intervention: Health check with screening, written feedback, and opportunity to discuss preventive health with general practitioner
Number of subjects: 1370
Study 7492424 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion with general practitioner
Number of subjects: 1370
Study 2024739 — intervention group
Group type: EXPERIMENTAL
Intervention: Secobarbital (100 mg daily)
Number of subjects: 0
Study 2024739 — intervention group
Group type: EXPERIMENTAL
Intervention: Secobarbital (200 mg daily)
Number of subjects: 0
Study 2024739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (1 g/kg daily)
Number of subjects: 0
Study 6120716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propranolol or metoprolol
Number of subjects: 0